Clinical Inquiry: Do ACE inhibitors or ARBs help prevent kidney disease in patients with diabetes and normal BP?

Abstract

Yes for angiotensin-converting enzyme (ACE) inhibitors, no for angiotensin receptor blockers (ARBs). A 2011 meta-analysis of 5 RCTs (total 2975 patients) that compared ACE inhibitor therapy with placebo in diabetic patients without hypertension and albuminuria found that ACE inhibitors reduced the risk of new-onset microalbuminuria or macroalbuminuria by 18% (relative risk [RR]=0.82; 95% confidence interval [CI], 0.73-0.92).

• Authors: Gregory S Trietley, Stephen A Wilson, Parul Chaudhri, Nicole Payette, Ashley Higbea, Joan Nashelsky
• Journal: The Journal of family practice (J Fam Pract) Vol. 66 Issue 4 Pg. 257-263 (Apr 2017) ISSN: 1533-7294 [Electronic] United States
• PMID: 28375400 (Publication Type: Comparative Study, Journal Article, Meta-Analysis)

Chemical References

• Angiotensin Receptor Antagonists
• Angiotensin-Converting Enzyme Inhibitors
• Antihypertensive Agents

Topics

• Albuminuria (drug therapy, etiology)
• Angiotensin Receptor Antagonists (adverse effects, therapeutic use)
• Angiotensin-Converting Enzyme Inhibitors (adverse effects, therapeutic use)
• Antihypertensive Agents (therapeutic use)
• Blood Pressure (drug effects)
• Diabetes Complications (physiopathology)
• Humans
• Hypertension (drug therapy, etiology)
• Risk Assessment